Elevated plasma levels of antimicrobial polypeptides in patients with severe sepsis

Journal of Innate Immunity

Volumn 2, Issue 5, 2010, Pages 478-482

  Berkestedt, Ingrid ^a   Herwald, Heiko ^b   Ljunggren, Lennart ^c   Nelson, Axel ^a   Bodelsson, Mikael ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c MALMÖ UNIVERSITY   (Sweden)

Author keywords

Antimicrobial peptide; Bactericidal permeability increasing protein; Defensins; Heparin binding protein; LL 37; Sepsis

Indexed keywords

ALPHA DEFENSIN; ANTIMICROBIAL POLYPEPTIDE; BACTERIAL PROTEIN; HEPARIN BINDING PROTEIN; LACTOFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPSIS;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-DEFENSINS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CARRIER PROTEINS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; SEPSIS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 77956055988     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000317036     Document Type: Article

References (19)

1. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420: 885-891.
2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
3. Zasloff M: Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
4. Boman HG: Antibacterial peptides: basic facts and emerging concepts. J Intern Med 2003; 254: 197-215.
5. Sørensen OE, Borregaard N, Cole AM: Antimicrobial peptides in innate immune responses. Contrib Microbiol 2008; 15: 61-77.
6. Ciornei CD, Egesten A, Bodelsson M: Effects of human cathelicidin antimicrobial peptide ll-37 on lipopolysaccharide-induced nitric oxide release from rat aorta in vitro. Acta Anaesthesiol Scand 2003; 47: 213-220.
7. Berkestedt I, Nelson A, Bodelsson M: Endogenous antimicrobial peptide ll-37 induces human vasodilatation. Br J Anaesth 2008; 100: 803-809.
8. Calvano SE, Thompson WA, Marra MN, Coyle SM, de Riesthal HF, Trousdale RK, et al: Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability- increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg 1994; 129: 220-226.
9. Rintala E, Peuravuori H, Pulkki K, Voipio- Pulkki LM, Nevalainen T: Bactericidal/permeability- increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome. Intensive Care Med 2000; 26: 1248-1251.
10. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
11. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/ failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26: 1793-1800.
12. Kahn R, Herwald H, Müller-Esterl W, Schmitt R, Sjögren AC, Truedsson L, Karpman D: Contact-system activation in children with vasculitis. Lancet 2002; 360: 535-541.
13. Lam HS, Pak NG: Biochemical markers of neonatal sepsis. Pathology 2008; 40: 141-148.
14. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ, Giroir BP: Recombinant bactericidal/permeability- increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000; 356: 961-967.
15. Gabay JE, Scott RW, Campanelli D, Griffith J, Wilde C, Marra MN, Seeger M, Nathan CF: Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1989; 86: 5610-5614.
16. Gautam N, Olofsson AM, Herwald H, Iversen LF, Lundgren-Åkerlund E, Hedqvist P, Arfors KE, Flodgaard H, Lindbom L: Heparin- binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med 2001; 7: 1123-1127.
17. Thomas NJ, Carcillo JA, Doughty LA, Sasser H, Heine RP: Plasma concentrations of defensins and lactoferrin in children with severe sepsis. Pediatr Infect Dis J 2002; 21: 34-38.
18. Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001; 97: 3951-3959.
19. Wang Y, Agerberth B, Löthgren A, Almstedt A, Johansson J: Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J Biol Chem 1998; 273: 33115-33118.